Table of Contents
| << Previous Issue | May 2012 (Vol: 2012, Issue: 5) | Next Issue >> |
- Section: Licensing
-
Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal
-
ASLAN Pharmaceuticals Gains Third Pipeline Drug via Licensing Deal with Almirall
- Section: Mergers & Acquisitions
-
Amgen Forays into Turkish Generics Market with MN Pharmaceuticals Purchase
-
Watson to Become World’s Third Largest Generics Company with US$5.9 B Actavis Buyout
-
Jazz Pharmaceuticals Diversifies into Oncology with EUSA Pharma Purchase
-
Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition
-
Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug
-
GSK to Acquire Full Control of its Proteomics Partner Cellzome
-
Agilent Technologies Agrees to Acquire Dako for US$2.2 B in its Largest Deal to Date
-
InterMune Divests Declining Actimmune® to Focus on Esbriet®
-
Takeda Aims for Globalisation with Purchase of Brazilian Company Multilab
- Section: Research & Development
-
Epizyme Collaborates with Celgene to Develop Epigenetics-Based Targeted Cancer Therapeutics
RSS